Cefsulodin (CAS 62587-73-9) Suppliers and Product Information

Cefsulodin is a semi-synthetic, third-generation cephalosporin antibiotic with a narrow spectrum of activity. It was first synthesized and patented by the Takeda Pharmaceutical Company in 1977. Cefsulodin has specific activity against Pseudomonas aeruginosa and Staphylococcus aureus but little activity against other bacteria.

Cefsulodin is used in CIN (cefsulodin-Irgasan-novobiocin) agar to select for microorganisms such as E. coli. It has been used to study multidrug resistance-associated protein 4 in efflux transport of prostaglandin E2 across the mouse blood-brain barrier. Cefsulodin is also used to study the effect of expression, binding, and inhibition of PBP1 and other penicillin-binding proteins (PBPs) on bacterial cell wall mucopeptide synthesis.

Frequently Asked Questions

Q: What is the primary use of Cefsulodin?

A: Cefsulodin is primarily used as an antibiotic with specific activity against Pseudomonas aeruginosa and Staphylococcus aureus. It is also used in microbiological research and studies related to antibiotic resistance mechanisms.

Q: How is Cefsulodin administered?

A: Cefsulodin is typically administered parenterally (intravenously or intramuscularly). A 500 mg intravenous bolus dose achieves a plasma concentration of approximately 70 mg/L at the end of the injection, while the corresponding intramuscular dose achieves a peak concentration of around 15 mg/L.

Q: What is the half-life of Cefsulodin?

A: The plasma half-life of Cefsulodin is approximately 1.5 hours in patients with normal renal function. However, the half-life is linearly related to creatinine clearance and can increase to 10-13 hours in patients with impaired renal function.

Q: How is Cefsulodin eliminated from the body?

A: Cefsulodin is primarily eliminated via the kidneys, with most of the drug appearing in the urine within the first 6 hours after administration. There is some metabolism of the drug, but renal excretion is the main route of elimination.